LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE

BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD

CA, June 21, 2022 - LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on

developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve

as an independent director.

John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our

Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics.

He has extensive knowhow in the journey from clinical development to reimbursement and commercialization, as well as the establishment

of partnerships with the pharmaceutical industry, academic collaborators, distributors, insurance companies and governments to successfully

launch new oncology products."

Kovach continued, "Lixte is now in the clinical phase of development of LB-100, its first-in-class protein phosphatase 2A (PP2A)

inhibitor. Our goal is to demonstrate the potential of this novel anti-cancer compound as a major new addition to chemotherapy and immunotherapy

regimens. Mr. van der Baan will bring substantial experience and expertise in the commercialization of new modalities in the oncology

market to our Board of Directors as we continue the clinical development of LB-100."

LIXTE Biotechnology Holdings, Inc.

Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development

and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways

in cells on or off. Most cancer research over the past 30 years has focused on the "on" switches because the "off"

switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients.

LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, demonstrating that

LB-100 is readily tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical

data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies

or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept

clinical trials are in progress.

announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section

21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy

and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing,

costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as

"intend," anticipate," "believe," "estimate," "potential(ly)," "continue,"

"forecast," "predict," "plan," "may," "will," "could," "would,"

"should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the

assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the

date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that

the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently

subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated

in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory

policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This

discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at

http://www.sec.gov/edgar.shtml.

Phone: (631) 830-7092

Phone: (888) 289-5533